Jefferies Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Jefferies Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,200	Closed	-$1.7M	–	2019
2021 Q1	$1.7M	Buy	+11,200	New	+$1.55M	0.01%	736

Other funds holding VRCA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's VRCA Position: Q2 2021 in Review

Jefferies Group sold out of Verrica Pharmaceuticals (VRCA) in Q2 2021, closing a stake of 11,200 shares — an estimated $1.7M sold.

Jefferies Group first reported a position in VRCA in Q1 2021 and held it in 1 quarter. The position peaked at $1.7M in Q1 2021. 53 funds tracked by Wall St. Rank hold VRCA as of Q2 2021.

Jefferies Group reported no remaining Verrica Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 11,200 Verrica Pharmaceuticals shares in Q2 2021, an estimated $1.7M.
Jefferies Group first reported a position in Verrica Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Jefferies Group's Verrica Pharmaceuticals position peaked at $1.7M in Q1 2021.
53 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.